Quantitative Immunohistochemical Expression of GP88 in Invasive Ductal Carcinoma (IDC) of Human Breast Cancer

Mona Abdel-Hamed Yehia (mona.a.yehia@gmail.com)  
Alexandria University Medical Research Institute  
https://orcid.org/0000-0003-1046-4952

Shawky Mohamed El-Fiky  
Alexandria University Medical Research Institute

Sabaheh Ali AL-Qadasi  
Sana'a university

Amel Sobhey El-Sedfy  
Alexandria University- Medical Research Institute

Research article

Keywords: HER2/neu., GP88, Clinical pathological parameter, IDC, IOD

DOI: https://doi.org/10.21203/rs.3.rs-66892/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Progranulin or acrogranin is an 88-kDa glycoprotein identified by a biological screen for protein targets associated with high tumorigenicity. This work was aimed to investigate the digital expression of GP88, and HER2/neu as a predictive biomarker in human invasive ductal carcinoma (IDC) versus benign tumors and normal breast tissues, as well as, its correlation with different pathological parameters.

Methods: The immunohistochemical avidin-biotin complex protocol of the paraffin section was used to detect the expression of GP88 and HER2/neu in IDC of 60 patients, 30 benign, and ten normal breast tissues.

Results: the study showed a high expression of GP88 in IDC comparing to normal and benign breast tissues. A higher significant statistical correlation between the expression of GP88 and large tumor size, tumor grade, and lymph node metastasis (LNM). While a negative statistical correlation was noticed between the expression of GP88 and ER, PR, and HER2/neu status.

Conclusion: It could be concluded that GP88 glycoprotein may be a valuable predictive and therapeutic marker in human IDC patients.

Introduction

Breast cancer represents a major scientific, clinical and societal problem. It is the most common malignancy and the second leading cause of cancer death in females following lung cancer [1, 2] with more than million new cases and 370,000 deaths yearly worldwide [3]. In many developing countries, the incidence of breast cancer is now rising sharply due to changes in reproductive factors, lifestyle, and increased life expectancy [4]. The invasive ductal carcinoma is the most common type of breast cancer, and comprises 70–80% of all cases. It starts in a milk duct of the breast, breaks through the wall of the duct, and grows into the fatty tissue of the breast, that it may be able to spread (metastasize) to other parts of the body through the lymphatic system and blood stream[5]. The cells invasive must occur from detached and penetrate the basement membrane, adherent cells lose their normal attachment to the substrate[6]. Proliferation is highly sensitive to the extracellular matrix maintain an actively proliferating phenotype in the newly encountered matrix [7]. Ductal carcinoma is an ill-defined mass, sometimes adherent to the skin or underlying muscle. The tumor is of varying size and may be associated with calcification. The histomorphology of the tumor is highly variable, ranging from a low-grade tumor showing mildly pleomorphic tumor cells arranged in tubules with little mitotic activity to a high-grade tumor showing highly pleomorphic tumor morphology, with the tumor cells arranged in solid sheets and groups, brisk mitotic activity and abundant tumor necrosis [8]. The Nuclear morphology is evaluated in variation of nuclear size, regularity of the nuclear border, hyperchromasias, and prominence of nucleolus. Also, it has been reported that histologic grade for breast cancer remains a prognostic factor despite changes in tumor size and number of positive lymph nodes [9]. Histological grade is commonly employed
and has been shown to be of independent prognostic significance. The studies showed very strong correlation with prognosis; patients with grade I tumors have a significantly better survival than those with grade II and III tumors (p < .0001) [10]

Progranulin is 88-kDa glycoprotein and known as GP88, PC-cell derived growth factor or acrogranin, GP88 gene is located on the 21q portion of chromosome 17, while the mouse gene was found on chromosome 11[11]. The autocrine growth factor GP88 is abundantly expressed in epithelial cells, immune cells, neurons, and chondrocytes[11]. Also, involved in a variety of biological processes, including embryogenesis, inflammation [12], wound healing[13], host defense [14] and cartilage development and degradation[15]. The importance of the Progranulin (GP88) is no unique receptor for GP88 has been identified[16]. GP88 has been shown to bind the membrane proteins sortilin and tumor necrosis factor receptors (TNFR) 1 & 2[17]. It is thought to exert its mitogenic effect through the stimulation of both the mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K) pathways[18]. GP88 stimulates the expression of the angiogenic growth factor (VEGF) in breast cancer cell lines, the breast cancers with elevated GP88 levels have higher VEGF levels and microvascular density [19]. GP88 is an important marker in breast cancer, it can be measured in healthy and breast cancer patients[20]. Increased secretion of GP88 is associated with more aggressive forms of breast, brain, renal, cervical and other tumors [12]

HER-2/neu (also called c-erbB-2) is a proto-oncogene located on chromosome 17, and encodes a 185-kd transmembrane glycoprotein receptor (p185 HER2) which has a tyrosine kinase activity and related to the epidermal growth factor receptor (EGFR). It is amplified or overexpressed in about 25–30% of human breast cancer, which is associated with tumor aggressiveness [11], and maybe related to variability in the interpretation of protein expression levels [21]. The predictive value of HER-2/neu status with respect to response to therapy as hormonal therapy, resistance to alkylating agent-based chemotherapy and taxanes [22, 23]. So, the aim of the present work was designed to study the Immunohistochemical expression of the GP88 as a novel prognostic biomarker in human invasive breast carcinoma.

Materials And Methods

Tissue samples were obtained from patients diagnosed with breast tumors in the Department of Pathology, Medical Research Institute (MRI), Alexandria University, Egypt, Formalin-fixed and paraffin embedded tissue specimens from 60 patients diagnosed with IDC, 30 patients diagnosed with benign breast tumor and 10 were taken from normal breast tissue adjacent to the benign tumors were included. All the cases were asked to freely volunteer to the study and informed written consents were gathered prior to their inclusion in the study according to the guide ethics of institute MRI (IORG#: IORG0008812). Samples from all studied cases were subjected to the following: 1-Clinical parameters included patients’ age, tumor size, lymph node metastasis (LNM) status, 2-Histopathological examination by hematoxlin and eosin (H&E) stained slides for each patient and reviewed by two pathologists (Diagnosis of the specimens was made according to the WHO classification of the Tumors) [24]. 3- Biological markers of (ER, PR). 3-Immunohistochemical technique: the detection of both GP88 and HER2/neu protein used
avidin biotin complex protocol (ABC) and DAB stain [25] Immunohistochemical method was utilized to study the expression of GP88 and HER2/neu. in 100 paraffin-embedded breast tissues. In brief; paraffin-embedded specimens were cut into 5µm sections. The sections were deparaffinized using 2 changes of xylene and rehydrated. The sections were submerged in antigen retrieval (citrate buffer saline pH 6) in an oven at 95°C for 20 minutes and then left at room temperature for 20 minutes to cool. The sections were treated with 3% H$_2$O$_2$ in PBS to quench the endogenous peroxidase activity, followed by incubation with serum blocking reagent for 30 minutes to block nonspecific binding. The sections were incubated with primary antibody for GP88 (Biorbyt Company, London, UK) and HER2/neu (Novus Biologicals Company, USA) at 4°C overnight. The sections were treated with conjugated 2' antibody (ABC-HRP reagent) for 30 minutes, stained with diaminobenzidine (DAB) and counter stained with hematoxylen. For negative controls, antibody was replaced with PBS. Each step was followed by PBS washing.

Immunohistochemical evaluation of results was arbitrarily graded as negative (0), weak (+1), moderate (+2) and strong (+3). 4- Image analysis: Integrated optical density (IOD) of GP88 and HER2/neu in normal, benign and IDC groups was analyzed using digital image analyzer. Images were viewed and recorded using Olympus microscope equipped with spot digital camera and image J software. Maximum, minimum and integrity of intensity color based on Gray-level acquisition, analysis of data were carried out by reading ten image for each case. The mean values of each reaction were based on the mean of pixel number [26]. IOD based on Gray-level transition probabilities in digitized images was graded from dark to light (0 up to 250). The average score across the whole image should be taken; IOD in digitized images was calibrated from strong to light (180 down to 70) by pixel. This calculation was proceed after subtract the pixel value from 250, the pick of lighter elimination.

**Results**

1- Histopathological investigation:

The parafin section photomicrograph illustrated the histopathological changes of the studies groups. The normal breast tissue showed acini lined by epithelial cells, an intact myoepithelial cell layer attached the basement membrane of acini (Figure 1A). A mild adenosis and cyst formation with mild epithelial hyperplasia in the adjacent duct and intact myoepithelial cell layer in fibrocystic disease of the benign breast case (Figure 1B). The tumor cells of invasive ductal carcinoma cases have abundant eosinophilic cytoplasm and large moderately pleomorphic round to ovoid vesicular nuclei arranged in cords and some contain small nucleoli. Infiltrated tumor cells in desmoplastic stroma represented GII (Figure1C). The neoplastic growth formed of nests and tubules and hyperchromatic nuclei and largely pleomorphic vesicular nuclei were exhibiting mitotic activity in ductal epithelial cells with many pyknotic cells, as well as, many residual nuclei was seen in GIII (Figure 1D).

The histopathological diagnosis of studing cases found that the benign cases revealed as the majority (83%, 25/30) of fibroadenoma, while 17% (5/30) cases were represented with fibrocystic disease. At malignant cases, there was a majority of invasive ductal carcinoma (IDC) (98%, 59/60), while 2% (1/50) of the malignant cases were represented with invasive lobular carcinoma (ILC). In addition, according to
Scarff-Bloom-Richardson histological grading system of breast cancer, the majority of the malignant cases diagnosed as grade II (45/60, 75%), grade III cases were represented by 22% (13/60) and the minority cases were grade I (2/60, 3%) of the malignant cases as in the (Table 1).

2- Clinicopathological parameters:

The age ranges of benign and malignant groups were 15-64 and 15-74 years with a mean ± SD of 36 ± 11 and 52 ± 10 years respectively. The data reported of the benign group cases 57% (17/30) at age range > 35-45 years versus of the malignant group cases 31.5% (19/60) at age ranges > 35-45 and > 45-55 years respectively. Neither of the benign cases were above 65 years nor of malignant cases under 25 years as shown in (Table 2).

According to the tumor size assessed according to TNM (Tumor, Node, Metastasis) staging system of breast cancer, there was 80% (24/30) of the benign cases were T2 (> 2-5 cm) versus 66% (27/45 grade II and 11/13 grade III) of the malignant cases were T2 (> 2-5 cm) as illustrated in the (Table 3). Whereas the percentage of positive vascular invasion (VI) was 98% (59/60) were distributed as in the (Table 4), as well as, Lymph Node Metastasis (LNM) was illustrated in the (Table 5). Also, Noticed the majority positive cases were represented (44/60, 3%) and free of lymph node metastasis cases were 16/60 (27%).

3- Semi-qualitative immunohistochemical staining:

Hormonal status of both estrogen and progesterone receptor (ER&PR) used as a biological marker in the malignant cases were differentiated to malignant grade II &III and illustrated in (Table: 6&7) respectively. According to epidermal growth factor receptor-2 (HER2/neu) expression, noticed that 53% (24/45) of IDC grade II were weak positive (-ve), while 38% (5/13) of IDC grade III were strong positive (3+), as shown in (Table: 8). As regard GP88 immunostaining expression resulted a moderate positive expression (2+) in 71% (32/45) of grade II IDC and strong (3+) in 77% (10/13) of grade III IDC as illustrated in (Table:9).

4- Immunohistochemical staining results:

Immunostaining expression of HER2/neu was detected as diffuse brown color detected in cell membrane of the ductal epithelial cells as shown in (Figure: 2 A,B,C,D).

Immunostaining expression of GP88 was detected as diffuse, homogenous brown color detected in the cytoplasm and membrane of the ductal epithelial cells of the studied groups as shown in (Figure: 3 A,B,C,D,E,F).

5- Immunostaining optical density (IOD)

A gray value detection of the binary evaluation at the 8-bit image of the stain density were quantitative digitally by pixel in the integrated region of optical density (ROD) as following:

a- HER2/neu
The mean and SD values of HER2/neu IOD for breast lesions illustrated the different ranges from 42.±3.82, 63.±5.34, 143±5.49 and 169±4.46 as control, benign and IDC grade II and III were respectively. There was statistically significant difference between benign group and malignant one, as well as between the malignant grade II and III of IDC (p < 0.001), as shown (Figure:4)

b- GP88

The mean and SD values of GP88 IOD for control, benign and IDC grade II and III were 35 ± 3, 41 ± 4, 140 ± 8 and 162 ± 7 respectively. A significant difference was noticed between GP88 IOD of grade II and III IDC and GP88 IOD of both control and benign groups (p < 0.001), but there was no statistical significant difference between GP88 IOD of control and benign groups (p = 0.1) as shown (Figure : 5)

c- Correlation between GP88 IOD and histopathological parameters:

There was no statistical significant correlation between the GP88 IOD and patients' age (r= -.14, P = .28), ER status (r= -.09, P = .50), PR status (r= .06, P= .65) and HER2/neu status (r.22, P= .08) of the studied breast cancer cases, while highly statistical significant correlation was noticed between the GP88 IOD and tumor size (r = .354**, P= .006), tumor grade (r= .353**, P= .006) and LNM status (r.493**, P = .000) as shown in table (10).

Discussion

Progranulin or GP88 is an autocrine growth factor and pleiotropic regulatory protein that has been shown to play role in tumorigenesis, including proliferation, survival, migration, angiogenesis invasion and matrix metallo-protease activity [27], as well as, in wound healing and in inflammation in normal tissues [28]. The study was evaluated the role of GP88 through the digital immunostaining density under the correlation with the clinical pathological parameter in the breast cancer lesions.

The study evaluated a statistical significant increase in the immunohistochemical expression of GP88 in IDC, versus, normal tissues and benign tumors (p< .001). This result is in alignment with previous finding reported a high level of GP88 expression in breast cancer biopsies versus benign lesions and normal mammary epithelial tissues [29, 30]. The pathological studies with 203 formalin-fixed paraffin-embedded human breast cancer tissue biopsies indicated that GP88 was preferentially expressed in ductal carcinoma with little expression in lobular carcinoma while benign lesions and normal mammary epithelial tissues were negative [31]. In addition, circulating GP88 level in the serum of breast cancer patients was increased in compared to healthy volunteers[28]. Moreover, the parental SW13 cells (cell derive from an adrenal carcinoma) poorly tumorigenic in vivo; however, by over-producing GP88, they become highly tumorigenic in mice [32, 33]. This finding revealed that the SW13 cells are highly sensitive to the proliferative effects of GP88. So, the digital analysis (IOD) of the GP88 in the present work revealed the role of the GP88 expression associated with the increased tumor grade in the breast cancer and detected its role in the proliferation and invasive of the tumor cell in breast tissue. Also, the immunostaining positivity of GP88 in this work revealed the marked and intensity was present in
malignant lesion and differentiated in both grade II and grade III, this results were indeed the role of the
GP88 expression induced and associated with division and invasive tumor cells. This finding was
confirmed by He, et al.,[33] who reported that the pgrn (GP88) stimulate cell division, invasion, and survival
demonstrates, other revealed the role of GP88 expression for regulates multiple processes or stages in
carcinoma progression and suggested the GP88 may be a possible future therapeutic target [34].

However, there was no statistically significant correlation between immunohistochemial expression of
GP88 and patients' age (r = -0.1, P = 0.3). This result is consistent with the results of other previous
studies [28, 35], who reported the clinical and tumor characteristics (p-value risk ratio 95% ) confidence
interval lower upper age in years Age ≤ 50 compared to > 50. Therefore, it could be agreed that the tissue
GP88 level is predictive of recurrence in patients with hormone-responsive BC [36], while the patients with
early-stage BC would be suggested that serum GP88 determination has the potential to have additional
clinical utility.

The large tumor size, high tumor grade, and positive lymph nodes are all signs of poor prognosis and
elevated GP88 expression have shown to be associated with tumorigenesis and poor prognosis in several
cancer types including ovarian [30], renal [37], prostate [38], liver [39], esophageal [40, 41] and breast
cancers [42]. The current study showed a highly statistically significant correlation between the
immunohistochemical expression of GP88 and tumor size (r = 0.354**, P = 0.006) of malignant breast
cases. This result is going in accordance with Li et, al., [38][35], but contrasted with Serrero et, al. [29] and
DeMorrow, [42]. Moreover, a highly statistically significant correlation was observed in the current study
between GP88's immunohistochemical expression and tumor histological grade (r = .353**, P = .006).
This result is contrasted with Serrero et, al.,[29], but consistent with the other who reported that
overexpression of GP88 in 80% invasive ductal carcinoma, where it correlated with the clinical variables
of poor prognosis such as tumor grade, p53 expression and Ki67 index[31, 35]. Immunohistochemical
expression of GP88 in the present study exhibited a highly statistically significant correlation with LNM of
the studied breast cancer cases (r = .493**, P = .000). A previous study found that high levels of GP88
expression were closely correlated with clinicopathological parameters such as lymph node metastasis
[35]. The histopathological features are independent predictors of clinical outcomes such as lymph node
status, tumor size and tumor grade for invasive ductal carcinoma patients were based evidence that IHC
analysis of GP88 expression maybe help a predict treatment outcomes in a prognostic role. At the
correlation between the GP88 and hormonal status as a routine marker and necessary for the treatment
and therapy of BC, our results in IDC patients found no statistical significant correlation between the
digital quantitative immunohistochemical expression of GP88 and ER (r = .09, P = .50) and PR (r = .06, P
= .65) status. These results are conflicted with Song et. al., [43] who reported that GP88 positive staining
was more common in ER/PR negative samples than that in ER/PR positive tumors. The current results
are going in accordance with Tkaczuk, et al., [28] who observed no statistical correlation between GP88
expression and ER and PR levels. However, screening of GP88 expression in human breast cancer cell
lines indicated that GP88 was highly expressed in both ER positive and ER negative human breast
carcinomas[29, 44]. This lack of correlation between GP88's immunohistochemical expression and ER
status indicated that the growth factor receptors promotes proliferation without requiring ER-mediated growth signaling [45].

It has been reported that level of G P88 expression was a major determinant of the intrinsic activity of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3’-kinase (PI3K) in cell line studies suggesting that the mitogen-activated protein kinase and phosphatidylinositol 3’-kinase signaling pathways may be involved in the promotion of tumor invasion and migration by GP88 [16, 33]. However, the current study revealed no statistical significant correlation between the immunohistochemical expression of GP88 and HER2/neu status (r = 0.2, P = .08) of the studied breast cancer cases. This result is going in accordance with many studies reported that there was no correlation between expression of GP88 and HER2/neu, and indicated that GP88 and HER2/neu were independent biomarkers [28, 31]. Other investigator found that 25% of HER2-overexpressing biopsies (3+ by IHC) were strongly positive for GP88 [46] and the treatment of HER2-overexpressing cells with Trastuzumab decreased the levels of MAPK phosphorylation [47]. The results is going to that the activation of mitogen-activated protein kinase (MAPK) signaling pathways in breast cancer cells by the over-production of growth factors [43]. So, GP88 can activate MAPK signaling pathway and phosphorylated MAPK regardless of the HER2 expression levels, thereby GP88 is not necessarily dependent on HER2 overexpression, because it has its own ability to activate MAPK pathway [48]. This may be indicated that HER2/neu and GP88 are independent biomarkers.

Finally, the study found that high progranulin expression was associated with higher breast histopathological features, which are strong independent predictors of clinical outcomes such as lymph node status, tumor size and tumor grade for patients with invasive ductal carcinoma, as well as, the digital quantitative immunostaining of GP88(IOD) in IDC cases was evident a high statistically significant correlation compared to the benign and malignant cases as well as between the IDC grade II and grade III (p = 0.0001). Beside of no correlation between GP88 with ER, PR, and HER2/neu expression.

**Conclusion**

It may be suggested that the GP88 involved in processes of cells invasive, regulate tumor cell progression and a biomarker dependent as a therapeutic target.

**Declarations**

**Ethics consents:**

All the cases were asked to freely volunteer to the study and informed written consents were gathered prior to their inclusion in the study according to the guide ethics of institute MRI (IORG#: IORG0008812).

**Consent for publication:** the co-author's consent to the publication .

**Availability of supporting data:** not applicable
Competing interests: None to declare

Funding:
The current work is not receipt of any research funding from any organization or any research grants

Authors’ contributions:
Mona Abdel-Hamed Yahia (Email: mona.a.yehia@gmail.com)
Prof. Dr. Histochemistry and Cell Biology (Ph.D.)
Idea of research, made the practical of immunohistochemistry staining and image analysis parts as well as wrote the articles.

Shawky Mahamed EL-Fiky
Prof. Dr. Histochemistry and Cell Biology (Ph.D.)
Idea of research and reviewed the article.

Sabah Ali AL-Qadasi (Email: salqadasi@yahoo.com)
Assis.Prof. Histology (Ph.D.)
Collecting data, made the histopathology, histochemistry parts, and the statistic results.

Amel Sobhey AL Sedfy (Email: Amel_sobhy@hotmail.com)
Prof. Dr. Pathology (Ph.MD)
Help us for collecting sample, made the diagnosis of sample and reviewed the present results.

Acknowledgments
The authors wish to thank the Cooperative of the Surgery and Pathology Departments of the Medical Research Institute for providing the breast cancer cases doe the study along with clinical information.

References
1. Khan HM, et al. Black Hispanic and Black non-Hispanic breast cancer survival data analysis with half-normal model application. Asian Pac J Cancer Prev. 2014;15(21):9453–8.
2. Byers T, et al. The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: results and reflections. Cancer J Clin. 2016;66(5):359–69.
3. Lehner J, et al. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy. Clinica chimica acta. 2013;425:206–11.

4. Forouzanfar MH, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. The lancet. 2011;378(9801):1461–84.

5. Smith RA, et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. Cancer J Clin. 2014;64(1):30–51.

6. Pandya S, Moore RG. Breast development and anatomy. Clin Obstet Gynecol. 2011;54(1):91–5.

7. Cameron MD, et al. Temporal progression of metastasis in lung: cell survival, dormancy, and location dependence of metastatic inefficiency. Cancer research. 2000;60(9):2541–6.

8. Young B, Woodford P, O'Dowd G, Wheater's Functional Histology E-Book: A Text and Colour Atlas. 2013: Elsevier Health Sciences.

9. Schwartz AM, et al. Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER Program. Arch Pathol Lab Med. 2014;138(8):1048–52.

10. Harris JR, et al., Diseases of the Breast. 2012: Lippincott Williams & Wilkins.

11. Liu C-j, Bosch X. Progranulin: a growth factor, a novel TNFR ligand and a drug target. Pharmacol Ther. 2012;133(1):124–32.

12. Bateman A, Bennett HP. The granulin gene family: from cancer to dementia. Bioessays. 2009;31(11):1245–54.

13. Halper J. Growth factors as active participants in carcinogenesis: a perspective. Veterinary pathology. 2010;47(1):77–97.

14. Yin F, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207(1):117–28.

15. Feng JQ, et al. Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis. FASEB J. 2010;24(6):1879–92.

16. Lu Y, et al. Growth factor progranulin contributes to cervical cancer cell proliferation and transformation in vivo and in vitro. Gynecol Oncol. 2014;134(2):364–71.

17. De Muynck L, Van Damme P. Cellular effects of progranulin in health and disease. J Mol Neurosci. 2011;45(3):549.

18. Cuevas-Antonio R, et al. Expression of progranulin (Acrogranin/PCDGF/Granulin-EpitheLin Precursor) in benign and malignant ovarian tumors and activation of MAPK signaling in ovarian cancer cell line. Cancer investigation. 2010;28(5):452–8.

19. Toh H, et al. Expression of the growth factor progranulin in endothelial cells influences growth and development of blood vessels: a novel mouse model. PloS one. 2013;8(5):e64989.

20. Giuliano AE, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. Jama. 2011;305(6):569–75.
21. Orucevic A, et al. Is the TNM Staging System for Breast Cancer Still Relevant in the Era of Biomarkers and Emerging Personalized Medicine for Breast Cancer–An Institution’s 10-year Experience. Breast J. 2015;21(2):147–54.

22. Romond EH, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

23. Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer. Clinical advances in hematology & oncology: H&O, 2006. 4(3 Suppl 7): p. suppl 1, 4–9; discussion suppl 10; quiz 2 p follow.

24. Bansal C, et al., Comparative evaluation of the modified Scarff-Bloom-Richardson grading system on breast carcinoma aspirates and histopathology. Cytojournal, 2012. 9.

25. Buchwalow IB, Böcker W. Immunohistochemistry: Basics Methods. 2010;1:1–149.

26. Matos LLd, et al. Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis. Clinics. 2006;61(5):417–24.

27. Edelman MJ, et al. GP88 (progranulin): a novel tissue and circulating biomarker for non–small cell lung carcinoma. Human pathology. 2014;45(9):1893–9.

28. Tkaczuk KR, et al. Increased circulating level of the survival factor GP88 (Progranulin) in the serum of breast cancer patients when compared to healthy subjects. Breast cancer: basic clinical research. 2011;5:BCBCR. S7224.

29. Serrero G, et al. Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma. Breast Cancer Res. 2012;14(1):1–12.

30. Han JJ, et al. Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers. Gynecol Oncol. 2011;120(1):5–10.

31. Serrero G, Ioffe OB. Expression of PC-cell-derived growth factor in benign and malignant human breast epithelium. Human pathology. 2003;34(11):1148–54.

32. Zhang Y, Bateman A. The glycoprotein growth factor progranulin promotes carcinogenesis and has potential value in anti-cancer therapy. J Carcinogene Mutagene. 2011;2:001.

33. He Z, et al. Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer research. 2002;62(19):5590–6.

34. Arechavaleta-Velasco F, et al. Progranulin and its biological effects in cancer. Med Oncol. 2017;34(12):194.

35. Li LQ, et al. Progranulin expression in breast cancer with different intrinsic subtypes. Pathology-Research Practice. 2012;208(4):210–6.

36. Tkaczuk KH, et al. Association of Serum Progranulin Levels With Disease Progression, Therapy Response and Survival in Patients With Metastatic Breast Cancer. Clin Breast Cancer. 2020;20(3):220–7.
37. Donald CD, et al. Expression of progranulin and the epithelin/granulin precursor acrogranin correlates with neoplastic state in renal epithelium. Anticancer research. 2001;21(6A):3739.

38. Monami G, et al. Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth. Am J Pathol. 2009;174(3):1037–47.

39. Ho JC, et al. Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. Hepatology. 2008;47(5):1524–32.

40. Chen X-y, et al. Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin Med J. 2008;121(10):881–6.

41. Koo DH, et al. Progranulin as a prognostic biomarker for breast cancer recurrence in patients who had hormone receptor-positive tumors: a cohort study. PloS one. 2012;7(6):e39880.

42. DeMorrow S. Progranulin: a novel regulator of gastrointestinal cancer progression. Translational gastrointestinal cancer. 2013;2(3):145.

43. Song H, et al. Expression of PC-cell-derived growth factor in breast cancer. Frontiers of Medicine in China. 2009;3(4):426.

44. Lu R, Serrero G, Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468. Proceedings of the National Academy of Sciences, 2000. 97(8): p. 3993–3998.

45. Lilling G, et al. Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio? Cancer letters. 2000;161(1):27–34.

46. Kim WE, Serrero G. PC Cell–Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells. Clinical cancer research. 2006;12(14):4192–9.

47. Donnelly SM, et al. P38 MAPK contributes to resistance and invasiveness of HER2-overexpressing breast cancer. Curr Med Chem. 2014;21(4):501–10.

48. Kim J-H, et al. Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma. Cancer Chemother Pharmacol. 2016;78(5):1085–92.

**Tables**

**Table (1): Distribution of breast cancer regarding tumor grade**

| Tumor grade | No of the cases | %  |
|-------------|----------------|----|
| Grade I     | 2              | 3  |
| Grade II    | 45             | 75 |
| Grade III   | 13             | 22 |
| Total       | 60             | 100|
Table (2): Age distribution among the benign and malignant groups

| Age categories | Benign group | Malignant group | Total |
|----------------|--------------|-----------------|-------|
|                | No  | %  | No  | %  | No  | %  |
| 15-25          | 8   | 27 | 0   | 0  | 8   | 9  |
| >25-35         | 3   | 10 | 2   | 3  | 5   | 6  |
| >35-45         | 17  | 57 | 19  | 31.5| 36  | 40 |
| >45-55         | 1   | 3  | 19  | 31.5| 20  | 22 |
| >55-65         | 1   | 3  | 16  | 27 | 17  | 19 |
| >65            | 0   | 0  | 4   | 7  | 4   | 4  |
| Total no. of cases | 30  | 100 | 60  | 100 | 90  | 100% |
| Range          | 16-64 | 35-74 | 16-74 |
| Mean ±SD       | 35.6 ± 11.23 | 51.53 ± 9.6 | F: 49.1, P < 0.001** |

X2: Chi square test, *P* statistically significant **Calculated by the F-test for two means

Table (3): Tumor size distribution between the benign and breast cancer cases

| Tumor size (cm) | Benign group | Malignant group |
|-----------------|--------------|-----------------|
|                | No  | %  | No  | %  | No  | %  | No  | %  |
| T1 ≤ 2         | 2   | 7  | 5   | 11 | 1   | 8  |
| T2 > 2.5       | 24  | 80 | 27  | 60 | 11  | 84 |
| T3 > 5         | 4   | 13 | 13  | 29 | 1   | 8  |
| Total          | 30  | 100| 45  | 100| 13  | 100 |

X² = 5.22, *P* = 0.3 (test is not significant)

Table (4): Distribution of vascular invasion (VI) among breast cancer cases

| vascular invasion | Grade I | Grade II | Grade III |
|-------------------|---------|----------|-----------|
|                   | No. | %   | No. | %   | No.  | %  |
| Positive          | 2   | 100 | 44  | 98  | 13   | 100 |
| Negative          | 0   | 0   | 1   | 2   | 0    | 0   |
| Total             | 2   | 100 | 45  | 100 | 13   | 100 |

Table (5): Lymph node metastasis (LNM) status of breast cancer cases

| Lymph node metastasis | Grade I | Grade II | Grade III |
|-----------------------|---------|----------|-----------|
|                       | No. | %   | No. | %   | No.  | %  |
| Positive              | 0   | 0   | 35  | 78  | 9    | 69   |
| Negative              | 2   | 100 | 10  | 22  | 4    | 31   |
| Total                 | 2   | 100 | 45  | 100 | 13   | 100  |

Table (6): Estrogen Receptor (ER) distribution among breast cancer grades
X²: Chi square test

**Table (7): Progesterone Receptor (ER) distribution among breast cancer grades**

| Estrogen Receptor (ER) | Grade II | | Grade III | |
|------------------------|----------|---|----------|---|
|                        | No       | % | No        | % |
| Negative (-ve)         | 5        | 11| 3         | 23|
| Weak positive (1+)     | 10       | 22| 6         | 46|
| Moderate positive (2+) | 18       | 40| 3         | 23|
| Strong positive (3+)   | 12       | 27| 1         | 8 |
| Total                  | 45       | 100| 13        | 100|

X² = 5.6, p = 0.14 (statistically not significant)

**Table (8): HER2/neu distribution among breast cancer cases**

| HER2/neu     | Control group | Benign group | Malignant group | Total |
|--------------|---------------|--------------|-----------------|-------|
|              | Grade II      | Grade III    | Grade II        | Grade III |
|              | No | % | No | % | No | % | No | % | No | % |
| Negative (-ve) | 8  | 80| 12 | 40 | 8  | 18| 2  | 16| 30 | 31|
| Weak +ve(+1)   | 2  | 20| 16 | 54 | 24 | 53| 2  | 16| 44 | 45|
| Moderate +ve(+2) | 0  | 0 | 2  | 6 | 9  | 20| 4  | 30| 15 | 15|
| Strong +ve(+3) | 0  | 0 | 0  | 0 | 4  | 9 | 5  | 38| 9  | 9 |
| Total          | 10 | 100| 30 | 100| 45 | 100| 13 | 100| 98 | 100|

X²: Chi square test  

(X²=9.5, p=0.2 (no statistical significant))

**Table (9): GP88 immunostaining reactivity in the different studied groups**
| GP88          | Control group | Benign group | Malignant group | Total |
|--------------|---------------|--------------|-----------------|-------|
|              | Grade II     | Grade III    |                 |       |
| No | %    | No | %     | No | % | No | % | No | % |
| Negative (-ve) | 8 | 80 | 17 | 57 | 3 | 7 | 1 | 8 | 29 | 30 |
| Weak +ve(+1) | 2 | 20 | 11 | 37 | 4 | 9 | 0 | 0 | 17 | 17 |
| Moderate +ve(+2) | 0 | 0 | 1 | 3 | 32 | 71 | 2 | 15 | 35 | 36 |
| Strong +ve(+3) | 0 | 0 | 1 | 3 | 6 | 13 | 10 | 77 | 17 | 17 |
| Total | 10 | 100 | 30 | 100 | 45 | 100 | 13 | 100 | 98 | 100 |

$x^2$: Chi square test  

$(X^2=98.5 \ p=0.0001 \text{ (statistically significant)})$

Table (10): Correlation between GP88 IOD and histopathological parameter of cases studies

| Pathological parameters | Cath-D IOD |
|-------------------------|------------|
| Age                     | $r \ 0.05$  |
|                         | $p \ 0.68$  |
| Tumor size              | $r_s \ 0.04$ |
|                         | $p \ 0.77$  |
| Grades                  | $r_s \ 0.257^*$ |
|                         | $p \ 0.05$  |
| LNM                     | $r_s \ 0.351^{**}$ |
|                         | $p \ 0.006$  |
| ER status               | $r_s \ -0.12$ |
|                         | $p \ 0.35$  |
| PR status               | $r_s \ -0.17$ |
|                         | $p \ 0.2$  |
| Her2/status             | $r_s \ 0.301^*$ |
|                         | $p \ 0.02$  |